OncoMatch/Clinical Trials/NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Is NCT07015242 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for lymphoma.
Treatment: Rituximab · Methotrexate · Procarbazine · Temozolomide · Liso-cel · Fludarabine · Cyclophosphamide · Calcium folinate — The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: high-dose methotrexate-based regimen (methotrexate) — PCNSL
anti-cancer therapy for the treatment of PCNSL must be limited to HD-MTX based standard of care regimens with a minimum of 4 and maximum of 6 doses of MTX
Cannot have received: experimental treatment for PCNSL
No prior experimental treatments for PCNSL.
Cannot have received: CAR-T cell therapy
Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology.
Cannot have received: gene therapy product utilizing human genome-editing technology
Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology.
Cannot have received: allogeneic transplant
History of prior allogeneic transplant
Cannot have received: solid organ transplant requiring immunosuppressive therapy
solid organ transplant requiring immunosuppressive therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Of Colorado · Aurora, Colorado
- Moffitt Cancer Center · Tampa, Florida
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Chicago, Illinois
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Washington University School of Medicine in St. Louis · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07015242 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior experimental treatment for PCNSL, CAR-T cell therapy, gene therapy product utilizing human genome-editing technology disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages